Potent ferroptosis agent RSL3 induces cleavage of Pyroptosis-Specific gasdermins in Cancer cells
Scientific Reports · 2025
DOI: 10.1038/s41598-025-11368-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2025. Verfasst von William G Herrick und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 2170…. Hauptthemen laut MEDLINE: Pyroptosis, Ferroptosis, Neoplasms, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Ferroptosis is a form of iron-dependent cell death of interest for the development of novel anti-cancer therapies. Ferroptosis research uses a process of elimination based on assumed ferroptosis-specific inducers and inhibitors; these molecules however have off-target effects and cannot provide a comprehensive picture of overlapping pathways. We investigated whether pyroptosis—a form of inflammatory cell death—is initiated in cancer cells following treatment with the ferroptosis inducer RSL3. We treated 6 cancer cell lines with RSL3 alone or in combination with inhibitors of ferroptosis (Ferrostatin-1), caspases (zVADfmk), necroptosis (Necrostatin-1), BID (BI-6C9), or STING (H-151). Biomarkers of pyroptosis and ferroptosis were assessed using our novel quantitative multiplex immunoassay. Increased secretion of pyroptosis-associated cytokines (IL-1α, IL-1β, IL-18), and gasdermin D and E (GSDMD/E) cleavage with parallel loss of respective full-length proteins—both hallmarks of pyroptosis—were recorded in 5/6 cell lines following RSL3 treatment. RSL3 cytotoxicity was blocked by Ferostatin-1; BID and STING inhibitors also prevented GSDMD/E cleavage. We conclude that the ferroptosis-inducer RSL3 triggers pyroptosis in cancer cells; further work is required to elucidate the role of mitochondria in this process. Measurement of pathway-specific protein biomarkers is therefore necessary to identify the exact mechanism of action of novel cytotoxic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702, USA.
- Protein Expression Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702, USA.
- Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA.
- Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
- Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702, USA. Srivastavaa4@nih.gov.
Förderung
- National Cancer Institute
Zitieren
APA
Herrick, W. G., Tran, H. L., Tomaino, F. R., Beall, B., Govindharajulu, J., Esposito, D., Kuhlmann, L., Parchment, R. E., Doroshow, J. H., & Srivastava, A. K. (2025). Potent ferroptosis agent RSL3 induces cleavage of Pyroptosis-Specific gasdermins in Cancer cells. Scientific Reports. https://doi.org/10.1038/s41598-025-11368-1
Vancouver
Herrick WG, Tran HL, Tomaino FR, Beall B, Govindharajulu J, Esposito D, et al. Potent ferroptosis agent RSL3 induces cleavage of Pyroptosis-Specific gasdermins in Cancer cells. Scientific Reports. 2025. doi:10.1038/s41598-025-11368-1
BibTeX
@article{Herrick2025,
author = {Herrick, William G and Tran, Huong-Lan and Tomaino, Francesca R and Beall, Brittany and Govindharajulu, Jeevan and Esposito, Dominic and Kuhlmann, Laura and Parchment, Ralph E and Doroshow, James H and Srivastava, Apurva K},
title = {Potent ferroptosis agent RSL3 induces cleavage of Pyroptosis-Specific gasdermins in Cancer cells},
journal = {Scientific Reports},
year = {2025},
doi = {10.1038/s41598-025-11368-1}
}
EUVIMED